Table 4 Association of clinical characteristics and platinum sensitivity
From: Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis
Characteristic | Platinum-sensitivity | Platinum-resistance | p* |
|---|---|---|---|
Frequency (%) | Frequency (%) | ||
Family History of Breast or Ovarian Cancer | |||
No | 10 (55.6) | 8 (44.4) | 1.000 |
Yes | 3 (60.0) | 2 (40.0) | |
Histology | |||
HGCS | 10 (52.6) | 9 (47.4) | 1.000 |
Other histologies | 2 (66.7) | 1 (33.3) | |
FIGO stage | |||
I-III | 11 (55.0) | 9 (45.0) | 1.000 |
IV | 2 (50.0) | 2 (50.0) | |
Residual disease after primary surgery | |||
< 1 cm | 12 (66.7) | 6 (33.3) | 0.014 |
≥ 1 cm | 0 (0) | 5 (100) | |
Disease progression outside CNS | |||
No | 8 (57.1) | 6 (42.9) | 1.000 |
Yes | 6 (54.5) | 5 (45.5) | |
Number of metastasis | |||
1 | 6 (66.7) | 3 (33.3) | 0.423 |
> 1 | 7 (46.7) | 8 (53.3) | |
Largest size of brain metastasis | |||
< 3.2 cm (median) | 5 (50.0) | 5 (50.0) | 0.650 |
≥ 3.2 cm (median) | 6 (66.7) | 3 (33.3) | |
Number of previous lines of CT | |||
< 3 | 11 (78.6) | 3 (21.4) | 0.017 |
s≥ 3 | 3 (27.3) | 8 (72.7) | |
Death directly related to BM | |||
No | 2 (40.0) | 3 (60.0) | 1.000 |
Yes | 7 (53.8) | 6 (46.2) | |